Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Long-Term Infliximab for Psoriasis (P05319)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant must have a diagnosis of plaque-type psoriasis~* Participant's physician must have decided, with the subject's consent, to start treatment with infliximab~* Participant must demonstrate willingness to participate in the study and agree with the procedures of the study by signing the written informed consent~* For inclusion into the extended treatment period, participant must have completed 50 weeks of infliximab treatment in the treatment period~* For inclusion into the extended treatment period, participant must be continuing treatment with intravenous infliximab~* For inclusion into the extended treatment period, participant must have an improvement in their PASI score of greater than or equal to 25% at the time of entry into to the extended treatment period~Exclusion Criteria:~For the Treatment Period~* Given the non-interventional nature of the study, no specific exclusion criteria will be applied to a participant so long as the participant is eligible for the trial (Inclusion Criteria). The treating physician is expected, as in normal clinical practice, to follow the PM (Canada), the approved SPC (EU), or local labeling (for all other participating countries) regarding contraindications and precautions~For the Extended Treatment Period~* Given the non-interventional nature of the study, no specific exclusion criteria will be applied to a participant so long as the participant is receiving infliximab treatment in accordance with the PM (Canada), the approved SPC (EU), or local labeling (for all other participating countries) regarding contraindications, precautions, dosing and frequency of administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infliximab 5 mg/kg (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).